oppn parties Prescriptions, Generic Names, Legibility and Resistance By Doctors

News Snippets

  • Supreme Court questions the continuing relevance of two-child norms. The Court observed that falling fertility rates have weakened the population-control rationale behind laws disqualifying people with more than two children from contesting local body elections. It referred the issue to a larger Bench for consideration
  • Supreme Court declines to shift Tirupati laddu case outside Andhra Pradesh. The Court rejected a plea seeking transfer of the trial, despite arguments that political statements by Andhra Pradesh's Chief Minister and Deputy Chief Minister could affect the fairness of proceedings
  • Supreme Court transfers Azam Khan's fresh ED bail plea to Allahabad High Court. The apex court declined to consider the Samajwadi Party leader's bail request in a fresh Enforcement Directorate case and directed that it be listed before a division Bench of the High Court on November 16
  • Two killed in Delhi building collapse; contractor booked. Two bodies were recovered after a building collapsed in Chawri Bazaar. Delhi Chief Minister Rekha Gupta said the contractor had been booked and the concerned junior and assistant engineers suspended
  • Uttar Pradesh voter rolls show a 2.4-crore discrepancy. A difference of approximately 2.4 crore names has been reported between the state's panchayat and rural Assembly voter lists. The Election Commission has ordered the two sets of rolls to be matched
  • Gujarat announces 3% dearness allowance hike. The state government announced a three-percentage-point increase in dearness allowance for government employees and pensioners ahead of Diwali
  • Sensex and Nifty post their strongest single-day gains in months. The Sensex surged 2,008.61 points, or 2.60%, to close at 79,310.01, while the Nifty 50 climbed 576 points, or 2.40%, to 24,536.60. Financial and automobile stocks led the rally, supported by falling crude prices and renewed foreign investor buying
  • Maaya Rajeshwaran reaches WTA-level quarter-final. The 17-year-old Indian defeated Poland's Weronika Falkowska 6-4, 6-3, becoming the first Indian woman since Sania Mirza in 2012 to reach a quarter-final at a WTA Tour-level singles event
  • Tanvi Patri reaches Youth Olympics badminton final. The 15-year-old defeated Japan's Yuzuno Watanabe in the semi-final, assuring India of a medal and becoming the first Indian badminton player to reach the girls' singles final at the Youth Olympics
  • India beat Pakistan 3-2 in SAFF Championship. India defeated Pakistan in a closely contested match, having led 3-0 before conceding two late goals. The victory was reported as a significant result for India's second-string side
  • India beat Japan 4-1 to win a record sixth Asian Champions Trophy. India recovered from an early deficit to defeat Japan in the final at Mohali, extending its record as the tournament's most successful men's team
  • The Supreme Court issued notice to the Centre and the Election Commission on a petition challenging Section 16 of the Chief Election Commissioner and Other Election Commissioners Act, 2023, which grants the CEC and Election Commissioners protection from legal proceedings for acts performed in their official duties. The petition argues that such blanket immunity could leave citizens without an effective remedy for alleged wrongdoing by the Commission
  • The Supreme Court told voters whose names were deleted from Delhi's draft electoral rolls not to be apprehensive about seeking re-enrolment through Form 6, after the Election Commission assured it that such applicants would not be prosecuted merely because their names had appeared in earlier rolls
  • Congress leader Rahul Gandhi opened the party's campaign for the 2027 Punjab Assembly elections with an Insaaf rally in Sangrur, Chief Minister Bhagwant Mann's home district, accusing the AAP government of failing to control drugs, gangster violence and corruption. Congress president Mallikarjun Kharge outlined six commitments, including a drug-free Punjab, protection of farmers, employment for young people and action against corruption
  • Rahul Gandhi accused the AAP government of running Punjab through a remote control from Delhi and questioned Bhagwant Mann's ability to tackle drug abuse, making personal allegations about the Chief Minister's conduct during their time together in Parliament
Stock markets on fire due to US results, Sensex gains 2008 points to reach its highest level in 8 months
oppn parties
Prescriptions, Generic Names, Legibility and Resistance By Doctors

By Sunil Garodia
First publised on 2016-10-20 20:06:00

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator. Author of Cyber Scams in India, Digital Arrest, The Money Trap and The Human Hack
image courtesy: drugsdiscovery.com

Doctors, individually and some of their professional associations, have always resisted attempts to introduce best practices in writing prescriptions. Backed by the strong drugs manufacturers’ lobby, doctors have steadfastly refused to follow international norms of writing prescriptions of medicines by their generic chemical names. They have always supplemented their incomes by loyally prescribing drugs of particular companies. The companies reward them through various means that include cash, vehicles, consumer durables, laptops, high-end mobile phones, local and foreign vacations and trips to medical jamborees. For the patient, this results in higher spending on medicines as most brands that indulge in ‘bribing’ the doctors to prescribe their products end up charging the same to the patient. Their drugs are much costlier than the competition, but since doctors prescribe them, the layman patient has no option but to buy the same.

The Medical Council of India (MCI) has recently decreed that doctors should prescribe medicines by their generic chemical names and write prescriptions in capital letters to make them legible. But doctors have not started doing the same, taking the plea that since the word used is “should,” it is just an advisory and not a legally binding directive. Vinod Monga, the dean of Indian Medical Association (IMA)’s College of General Practitioners is quoted as saying that “there is a difference between “should” and “shall” – should implies this is only the MCI’s expectation, an advisory.” This must rank as the mother of all excuses. Doctors must see beyond words and look at the intention behind the reform. But since it is going to pinch their pocket, they are trying to create confusion. But they do not know that since the glare is now on them, they will have to write prescriptions that way, sooner rather than later. The MCI must immediately issue a fresh directive and drop “should” to replace it with “must,” leaving nothing to imagination.

Many doctors expressed concern about leaving the decision in the pharmacist’s hands as to which medicine to supply. This is not a valid concern. Pharmacies have registered pharmacists on their rolls and they are well qualified to dispense both single and combination drugs as per prescription, even if generic names are written. The drug administrator will now have to strictly monitor that pharmacies actually employ pharmacists rather than just show them on record and run the dispensaries on their own. The other concern that doctors do not see all brands as perfectly equal to each other is something that they have to take up with the government. If combination drugs are prescribed, a standard dosage has to be maintained. For instance, when an omeprazole/domperidone combination is prescribed, there are some brands that have 40 mg omeprazole with 5 mg domperidone, while others have 10mg domperidone. The pricing is also different. The government will have to consult with doctors and make a standard where either 5mg or 10 mg domperidone is allowed to be used. Then, many drugs now come in variations like “sustained release,” “extended release,” “controlled release” and others. These issues also need to be ironed out. Along with doctors prescribing generic names of drugs, the government needs to establish industry standards to avoid confusion in the minds of doctors, pharmacists and patients.

Lastly, there is also a need to educate the pharmacy owners and the end-users. Many times patients do not understand why they are being given a medicine different from what was prescribed by the doctor. They get into fights with the dispensing chemists for giving them wrong medicine. They refuse to understand that it is the same medicine of a different brand. Patients sometimes spend anxious hours, prescriptions in hand, hunting for the exact brand in various pharmacies. If generic names are prescribed, the frequency of these fights will increase and they might even become uglier. In fact, some pharmacy owners had attacked junior doctors of government hospitals in Kalyani in Bengal a few months ago over their practice of writing generic names of drugs. As most government hospitals in Bengal have fair price shops that sell low cost generic drugs, the pharmacy owners were agitated as they were losing business. Hence, a sustained campaign to educate the patient that the brand does not matter as long as the chemical name is correct needs to be undertaken – preferably at hospitals, medical stores, through doctors and NGO’s and by a campaign in the media. The patient must realize that it is for their own good and that their medical bills will come down. Only then will the system work. Otherwise, doctors will write generic names but will tell the patient verbally to buy a particular brand. Similarly, medical representatives will start offering higher commissions to pharmacies to sell their brands of a particular generic name. From doctors, the corruption will shift to pharmacies. That will negate the very basis of the reform. It will succeed only when the patient will ask the pharmacist to tell him the options and then select the brand according to his preferred pricing. The poor might opt for the low cost brand while the rich might go for the higher priced ones. Patient education to the shift from brand to generic names is a must if pharmacies are not to become the next hotbed of corrupt practices by drug companies and a lot of confusion is to be avoided.